Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!

Still Pipette-Filling Cryovials? There’s a Better Way

Still Pipette-Filling Cryovials? There’s a Better Way

In cell and gene therapy, where fill precision and cell viability can determine the success of an entire treatment, it's surprising how many...

Read More
International Women in Engineering Day

International Women in Engineering Day

Each year on 23 June, International Women in Engineering Day (INWED), led by the Women’s Engineering Society, shines a spotlight on the remarkable...

Read More
Ensuring cGMP compliance in cell and gene therapy manufacturing

Ensuring cGMP compliance in cell and gene therapy manufacturing

In the evolving field of cell and gene therapy (CGT), adherence to current Good Manufacturing Practice (cGMP) is crucial. This white paper provides...

Read More